Emergent BioSolutions Inc. (EBS)
NYSE: EBS · Real-Time Price · USD
8.88
+0.61 (7.38%)
At close: Nov 20, 2024, 4:00 PM
9.00
+0.12 (1.35%)
Pre-market: Nov 21, 2024, 7:39 AM EST
Emergent BioSolutions Employees
Emergent BioSolutions had 1,600 employees as of December 31, 2023. The number of employees decreased by 900 or -36.00% compared to the previous year.
Employees
1,600
Change (1Y)
-900
Growth (1Y)
-36.00%
Revenue / Employee
$703,438
Profits / Employee
-$130,500
Market Cap
481.16M
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| Treace Medical Concepts | 516 |
| UroGen Pharma | 201 |
| Acelyrin | 135 |
| Monte Rosa Therapeutics | 133 |
| Perspective Therapeutics | 119 |
| Alumis | 109 |
| Theravance Biopharma | 99 |
| Zevra Therapeutics | 69 |
EBS News
- 12 days ago - Emergent BioSolutions: Stock Surging Post Q3 Earnings Thanks To Papa Magic - Seeking Alpha
- 13 days ago - Mpox Vaccine Player Emergent BioSolutions Stock Jumps On Upbeat Annual Forecast, Expects Smaller Losses In 2024 - Benzinga
- 14 days ago - Emergent BioSolutions Inc. (EBS) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 14 days ago - Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa - GlobeNewsWire
- 4 weeks ago - Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024 - GlobeNewsWire
- 6 weeks ago - Emergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN® Nasal Spray to Help Combat the Opioid Epidemic - GlobeNewsWire
- 6 weeks ago - Emergent BioSolutions: Strategic Shifts Present A Turnaround Scenario - Seeking Alpha
- 2 months ago - Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA® (brincidofovir) to Support National Preparedness Efforts - GlobeNewsWire